This is the authors' abstract. We don't add key points for this paper.
Recombinant human bone morphogenetic protein-2 (rhBMP-2) has emerged as an alternative to autogenous bone grafts in maxillofacial surgery, reducing donor-site morbidity while promoting osteoinduction. This case report evaluates the 10-year outcomes of rhBMP-2 use for mandibular bone regeneration in a 55-year-old male with extensive periapical osteolytic lesions on teeth #23, #24, #25, and #26 linked to childhood trauma. Following extraction, curettage, and rhBMP-2 grafting with a collagen membrane and titanium mesh, 3 implants (2.9 × 12 mm) were placed after 6 months, followed by osseointegration and a connective tissue graft for prosthetic rehabilitation. Over 10 years, clinical and radiographic assessments indicated stable bone levels (<1 mm crestal loss) and implant success with no complications reported despite acknowledged risks of edema or carcinogenesis. This case aligns with the literature supporting rhBMP-2 efficacy (81.4% bone regeneration success) and underscores the importance of delivery systems in optimizing outcomes. Continued research investigating dosing and carriers is warranted to enhance its application in implant dentistry.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Schneider et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: